Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy-Reference-Cited by-同舟云学术

Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy

Published:2022-03-10 Issue:6 Volume:37 Page:1016-1021
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J of Gastro and Hepatol

Author:

Hasan Badar¹^ORCID,Tandon Kanwarpreet Singh¹,Miret Rafael²,Khan Sikandar²,Riaz Amir²,Gonzalez Adalberto¹,Rahman Asad Ur¹,Charles Roger¹,Narula Neeraj³^ORCID,Castro Fernando J.¹

Affiliation:

1. Department of Gastroenterology Cleveland Clinic Florida Weston Florida USA

2. Department of Internal Medicine Cleveland Clinic Florida Weston Florida USA

3. Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute McMaster University Hamilton Ontario Canada

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15806

Reference23 articles.

1. Inflammatory Bowel Disease

2. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease

3. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

4. Does a Personal or Family History of Malignancy Preclude the Use of Immunomodulators and Biologics in IBD

5. A Practical Guide to the Safety and Monitoring of New IBD Therapies

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

2. Hidradenocarcinoma in a Crohn’s patient on ustekinumab: A case report;SAGE Open Medical Case Reports;2024-01

3. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease;Cureus;2023-10-11

4. Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab);Case Reports in Gastrointestinal Medicine;2023-10-10

5. Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis;Clinical Gastroenterology and Hepatology;2023-08